Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 16/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | ADPRS | Q9NX46 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | EGFR | P00533 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17845601 | 0.84 | PARG (0.53) | PARGADPRS | |
| SCHEMBL17845291 | 0.79 | PARG (0.59) | PARGCYP1A2ALDH1A1NPSR1 | |
| SCHEMBL17845644 | 0.76 | PARG (0.53) | PARGCYP1A2ALDH1A1EGFR | |
| SCHEMBL17845357 | 0.75 | PARG (1.00) | PARGADPRS | |
| SCHEMBL17845425 | 0.73 | PARG (1.00) | PARG | |
| SCHEMBL17845556 | 0.66 | PARG (0.53) | PARGCYP1A2EGFR | |
| SCHEMBL17845467 | 0.65 | PARG (0.53) | PARGALDH1A1EGFR | |
| SCHEMBL17845315 | 0.64 | PARG (0.63) | PARG | |
| SCHEMBL17845475 | 0.63 | PARG (0.61) | PARG | |
| SCHEMBL17845304 | 0.62 | PARG (0.55) | PARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2025-07-10 | — | — | US | disclosed |
| US-12129236-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2024-10-29 | — | — | US | disclosed |
| CN-112979631-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2024-09-20 | — | — | CN | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-12-09 | — | — | US | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3907224-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2021-11-10 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| EP-3233845-B1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECH LTD (GB) | 2021-07-21 | — | — | EP | disclosed |
| CN-112979631-A | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-06-18 | — | — | CN | disclosed |
| US-10995073-B2 | PARG inhibitory compounds | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-05-04 | — | — | US | disclosed |
| CN-107295799-B | PARG inhibiting compounds | 癌症研究科技有限公司 | 2021-03-16 | — | — | CN | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2020-05-28 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-07-12 | — | — | US | disclosed |
| EP-3233845-A1 | PARG INHIBITORY COMPOUNDS | Cancer Research Technology Limited (GB) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
| WO-2016097749-A1 | PARG INHIBITORY COMPOUNDS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2016-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380539-A1 | PARG INHIBITORY COMPOUNDS | PARP11, PARG, PARP16 | PARG 2/4885CYP1A2 847/4885ADPRS 21/4885 |
| US-20180194738-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885CYP1A2 799/4885ADPRS 21/4885 |
| US-10995073-B2 | PARG inhibitory compounds | PARG, PARP11, PARP16 | PARG 1/4885CYP1A2 799/4885ADPRS 21/4885 |
| US-12129236-B2 | PARG inhibitory compounds | PARP11, PARG, PARP16 | PARG 2/4885CYP1A2 847/4885ADPRS 21/4885 |
| US-20200165208-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885CYP1A2 799/4885ADPRS 21/4885 |
| US-20250223266-A1 | PARG INHIBITORY COMPOUNDS | PARG, PARP11, PARP16 | PARG 1/4885CYP1A2 799/4885ADPRS 21/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.